Cover Image
Market Research Report

CSL Ltd - Product Pipeline Review - 2016

Published by Global Markets Direct Product code 240916
Published Content info 63 Pages
Delivery time: 1-2 business days
Price
Back to Top
CSL Ltd - Product Pipeline Review - 2016
Published: December 30, 2016 Content info: 63 Pages
Description

Summary:

Global Markets Direct's, 'CSL Ltd - Product Pipeline Review - 2016', provides an overview of the CSL Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CSL Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of CSL Ltd
  • The report provides overview of CSL Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses CSL Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features CSL Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate CSL Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for CSL Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding CSL Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC08185CDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CSL Ltd Snapshot
    • CSL Ltd Overview
    • Key Facts
  • CSL Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • CSL Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • CSL Ltd - Pipeline Products Glance
    • CSL Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • CSL Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • CSL Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CSL Ltd - Drug Profiles
    • (coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • antihemophilic factor (recombinant), single chain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-311 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-324 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-626 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-650 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-689 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • factor XIII (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fibrinogen (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • haptoglobin + hemopexin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PODCRC-OHS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bleeding and Clotting Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Hemophilia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • CSL Ltd - Pipeline Analysis
    • CSL Ltd - Pipeline Products by Target
    • CSL Ltd - Pipeline Products by Route of Administration
    • CSL Ltd - Pipeline Products by Molecule Type
    • CSL Ltd - Pipeline Products by Mechanism of Action
  • CSL Ltd - Dormant Projects
  • CSL Ltd - Company Statement
  • CSL Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CSL Ltd, Key Facts
  • CSL Ltd - Pipeline by Indication, 2016
  • CSL Ltd - Pipeline by Stage of Development, 2016
  • CSL Ltd - Monotherapy Products in Pipeline, 2016
  • CSL Ltd - Combination Treatment Modalities in Pipeline, 2016
  • CSL Ltd - Partnered Products in Pipeline, 2016
  • CSL Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • CSL Ltd - Out-Licensed Products in Pipeline, 2016
  • CSL Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • CSL Ltd - Pre-Registration, 2016
  • CSL Ltd - Phase III, 2016
  • CSL Ltd - Phase II, 2016
  • CSL Ltd - Phase I, 2016
  • CSL Ltd - Preclinical, 2016
  • CSL Ltd - Discovery, 2016
  • CSL Ltd - Pipeline by Target, 2016
  • CSL Ltd - Pipeline by Route of Administration, 2016
  • CSL Ltd - Pipeline by Molecule Type, 2016
  • CSL Ltd - Pipeline Products by Mechanism of Action, 2016
  • CSL Ltd - Dormant Developmental Projects,2016
  • CSL Ltd, Other Locations
  • CSL Ltd, Subsidiaries

List of Figures

  • CSL Ltd - Pipeline by Top 10 Indication, 2016
  • CSL Ltd - Pipeline by Stage of Development, 2016
  • CSL Ltd - Monotherapy Products in Pipeline, 2016
  • CSL Ltd - Combination Treatment Modalities in Pipeline, 2016
  • CSL Ltd - Out-Licensed Products in Pipeline, 2016
  • CSL Ltd - Pipeline by Top 10 Target, 2016
  • CSL Ltd - Pipeline by Route of Administration, 2016
  • CSL Ltd - Pipeline by Molecule Type, 2016
  • CSL Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top